Biotech News

Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance

Rapid Micro Biosystems (RPID)Rapid Micro Biosystems2026-06-25 13:46 ESTEarnings

Reports third quarter 2025 total revenue of $7.8 million , representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable

Open original release

Related news

RPIDRapid Micro Biosystems2026-06-25 13:46 EST

Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RPIDRapid Micro Biosystems2026-06-25 13:46 EST

Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering

RPIDRapid Micro Biosystems2026-06-25 13:46 EST

Rapid Micro Biosystems Reports First Quarter 2026 Financial Results

RPIDRapid Micro Biosystems2026-06-25 13:46 EST

Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026

RPIDRapid Micro Biosystems2026-06-25 13:46 EST

Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference

RPIDRapid Micro Biosystems2026-06-25 13:46 EST

Rapid Micro Biosystems to Present at 44th Annual J.P. Morgan Healthcare Conference

RPIDRapid Micro Biosystems2026-06-25 13:46 EST

Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

RPIDRapid Micro Biosystems2026-06-25 13:46 EST

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RPIDRapid Micro Biosystems2026-06-25 13:46 EST

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

RPIDRapid Micro Biosystems2026-06-25 13:46 EST

Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference

View all latest news

Rapid Micro Biosystems

Rapid Micro Biosystems is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

RPIDZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

RPIDZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

RPIDBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

RPIDGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

RPIDMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 2.01 USD
Market cap: 102.13M USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States